In the third orthotopic tumor model, the effect of the CCK-BR targeted NP to deliver siRNA to silence muKras and WT-Kras in immune competent mice bearing orthotopic syngeneic mT3 murine pancreatic cancer cells was evaluated. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.